The CMPSR continues to provide a resource for high quality collection and analysis of pharmacokinetic specimens. However, the CMPSR has greatly expanded to include collection, processing and analysis of clinical specimens for translational/correlative and pharmacodynamic studies associated with the Center's clinical trials program. Additional objectives of the CMPSR are to: 1) Provide a resource for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies;2) Develop translational components for investigator-initiated clinical trials;and 3) Identify and validate biomarkers and molecular signatures that are predictive of response to therapy and investigate drug activity, pharmacodynamic responses and mechanisms of acquired or innate resistance. Further, the CMPSR provides UC Davis clinical investigators a comprehensive resource for clinical trial protocol development, including standardized and/or trial-specific language for specimen collection, and development of correlative study scientific components. It also provides services for preclinical modeling and biologic investigations of novel agents and therapeutic combinations that can serve as rationale for study development. Resource personnel work closely with the CTSU and clinical trial investigators to incorporate comprehensive and meaningful correlative and pharmacokinetic components into each trial. Users of the CMPSR are primarily UC Davis Cancer Center clinical investigators developing clinical trials. The CMPSR involvement in a clinical trial may range from the collection and shipping of UCD patient blood specimens enrolled on a cooperative group study, to broader roles including development and implementation of specialized specimen collection procedures and novel assays, comprehensive molecular correlative analysis of trial specimens and preclinical in vitro or in vivo modeling to generate drug mechanism hypotheses that can be tested in the clinic. These efforts often include significant CMPSR input during trial protocol development. The CMPSR also services as a bridge between clinical investigators with other Shared Resources.
This resource handles biological specimens used to understand how cancer therapies work, how cancers can be detected, how the body processes drugs, and how various combinations of therapies can be more or less effective. The specimens and analytical studies are carried out in conjunction, for the most part, with cancer clinical trials. Its results are important to improving options for treating different types of cancers.
|Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004|
|Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87|
|Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :|
|Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896|
|Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182|
|Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331|
|Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162|
|Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529|
|Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91|
|Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589|
Showing the most recent 10 out of 836 publications